64,858 Shares in Bristol-Myers Squibb Co (NYSE:BMY) Bought by Resources Management Corp CT ADV

Resources Management Corp CT ADV bought a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, Holdings Channel.com reports. The fund bought 64,858 shares of the biopharmaceutical company’s stock, valued at approximately $3,289,000.

A number of other hedge funds have also modified their holdings of BMY. Garrett Wealth Advisory Group LLC purchased a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $26,000. Lenox Wealth Advisors LLC raised its position in shares of Bristol-Myers Squibb by 555.7% during the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 539 shares during the last quarter. Financial Gravity Wealth Inc. raised its position in shares of Bristol-Myers Squibb by 101.2% during the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 327 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Bristol-Myers Squibb by 52.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 230 shares in the last quarter. Finally, 1 North Wealth Services LLC purchased a new position in shares of Bristol-Myers Squibb in the third quarter worth $41,000. Institutional investors and hedge funds own 83.01% of the company’s stock.

Several equities analysts recently weighed in on BMY shares. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a research note on Wednesday, August 14th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 19th. Wolfe Research set a $66.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, September 13th. Finally, Gabelli assumed coverage on Bristol-Myers Squibb in a research report on Wednesday, November 27th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $57.95.

In other news, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the transaction, the insider now owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now directly owns 74,471 shares in the company, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.

BMY traded up $1.15 during trading hours on Wednesday, hitting $58.90. The company’s stock had a trading volume of 21,668,416 shares, compared to its average volume of 24,667,110. The stock has a market cap of $92.77 billion, a price-to-earnings ratio of 14.80, a P/E/G ratio of 1.32 and a beta of 0.70. The business’s 50-day moving average price is $56.18 and its 200-day moving average price is $49.50. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $59.17.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The business had revenue of $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. During the same quarter last year, the business earned $1.09 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb Co will post 4.38 earnings per share for the current year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: The mechanics of the bid-ask spread in trading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit